Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Rheumatology›Condition·Updated Jul 11, 2026·v1

Giant Cell Arteritis

Giant cell arteritis is a granulomatous large-vessel vasculitis of the elderly, characterized by cranial and large-vessel phenotypes. It is an emergency due to risk of blindness and stroke. Diagnosis relies on clinical suspicion, ultrasound (halo sign), and temporal artery biopsy. Management begins with high-dose glucocorticoids; adjunctive tocilizumab or methotrexate reduces steroid exposure. Long-term complications include aortic aneurysm, infection, and glucocorticoid toxicity. Structured screening for aortic aneurysm and cardiovascular risk reduction is essential.

High Evidence319 references·10,595 words·43 min read·v1
giant cell arteritistemporal arteritisvasculitislarge-vessel vasculitisrheumatologyophthalmologyaortic aneurysmtocilizumabglucocorticoids

Quick Reference

RxDrug of choice[[prednisone]] 40-60 mg/day orally or IV for acute flare; for organ-threatening disease (visual loss), IV [[methylprednisolone]] 1 g/day for 3 days. Adjunctive [[tocilizumab]] 162 mg SC weekly with 26-week prednisone taper for sustained remission.
AltAlternatives[[methotrexate]] 15-25 mg PO/SC weekly; [[upadacitinib]] 15 mg PO daily; [[abatacept]] 10 mg/kg IV monthly; [[mavrilimumab]] 150 mg SC every 2 weeks (investigational).
⊘AvoidAnti-TNF agents (infliximab, adalimumab, etanercept); non-dihydropyridine CCBs (diltiazem, verapamil), exacerbate heart failure if present; live vaccines during high-dose immunosuppression; [[methotrexate]] in pregnancy (contraindicated).
DxTest of choiceHigh-resolution ultrasound of temporal and axillary arteries (halo sign), first-line imaging with 88% sensitivity and 96% specificity. Temporal artery biopsy if ultrasound equivocal or negative but high suspicion.
ScKey score2022 ACR/EULAR classification criteria: age ≥50 mandatory; score ≥6 points (positive biopsy/halo +5, ESR≥50 or CRP≥10 +3, sudden visual loss +3, +2 for each of morning stiffness, jaw/tongue claudication, new headache, scalp tenderness, temporal artery abnormality, bilateral axillary involvement, aortic FDG-PET activity).
→When to referUrgent rheumatology referral for all suspected GCA; same-day ophthalmology referral for acute visual loss; consider vascular surgery for large-vessel stenosis or aneurysm.
Giant cell arteritis is a medical emergency requiring immediate high-dose glucocorticoids to prevent blindness and stroke. Early use of steroid-sparing agents (tocilizumab or methotrexate) reduces cumulative glucocorticoid exposure and long-term morbidity. Aortic imaging at diagnosis and at 5 years is essential for detecting aneurysm.
Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that preferentially affects the aorta and its extracranial branches, occurring almost exclusively in adults aged ≥50 years. It is a medical emergency because of its potential to cause permanent vision loss (11-15% of patients), cerebrovascular ischemic events, and aortic dissection. The disease encompasses cranial and large-vessel phenotypes, with the 2022 ACR/EULAR classification criteria (score ≥6) providing a validated framework. Immediate high-dose glucocorticoids are the cornerstone of acute management, and adjunctive therapy with tocilizumab or methotrexate reduces cumulative steroid exposure and improves outcomes.

Overview and Recommendations

Background

  • •Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis that preferentially affects the aorta and its extracranial branches, occurring almost exclusively in adults aged 50 years and older. Also called Horton disease or temporal arteritis, it is now recognized as a spectrum including cranial and large-vessel phenotypes.
  • •The disease is a medical emergency because of its potential to cause permanent vision loss in 11-15% of patients, cerebrovascular ischemic events (pooled prevalence 4%), and aortic dissection (15-year relative risk 6.86 compared to the general population). Incidence peaks at 23.1 per 100,000 person-years in those aged 80-84 years, with a female predominance (female-to-male ratio ~2.5:1).
  • •Two main clinical phenotypes dominate: cranial GCA, which involves the temporal arteries and presents with headache, scalp tenderness, jaw claudication, and vision loss; and large-vessel GCA (LV-GCA), characterized by aortic, subclavian, and axillary artery inflammation, often presenting with limb claudication and constitutional symptoms. A mixed phenotype is also recognized, and a subset of patients with polymyalgia rheumatica (PMR) have subclinical GCA detected by imaging.
  • •The 2022 ACR/EULAR classification criteria (mandatory age ≥50 years) assign points for positive temporal artery biopsy or halo sign on ultrasound (+5), ESR ≥50 mm/hr or CRP ≥10 mg/L (+3), sudden visual loss (+3), and various clinical features (jaw claudication, new temporal headache, scalp tenderness, etc.) at +2 each. A cumulative score of ≥6 classifies a patient as having GCA, with sensitivity 87% and specificity 94.8%.
  • •The pathogenic cascade begins with activation of resident adventitial dendritic cells via Toll-like receptors, recruiting CD4+ T cells that polarize into Th17 cells (driven by IL-6, IL-1β, IL-23) and Th1 cells (driven by IL-12). The IL-6/Th17/IL-17 axis fuels systemic inflammation, while the IL-12/Th1/IFN-γ axis orchestrates granulomatous inflammation and vascular wall damage. The former is highly glucocorticoid-sensitive; the latter is steroid-resistant, explaining why high-dose corticosteroids rapidly suppress systemic symptoms but may not fully control vessel-wall inflammation.
  • •Risk factors include female sex, Northern European ancestry, age ≥70, and prior herpes zoster infection (especially ophthalmic). Type 2 diabetes is paradoxically protective (OR 0.75). Clonal hematopoiesis (DNMT3A, TET2 mutations) is present in 55-61% of GCA patients and may define a higher-risk subgroup.

Evaluation

  • •Suspect GCA in any patient ≥50 years with new-onset headache (especially temporal, unilateral or bilateral, aching or throbbing), scalp tenderness, jaw claudication (the single strongest clinical predictor), or unexplained constitutional symptoms (fever, weight loss, malaise).
  • •Ask about transient monocular vision loss (amaurosis fugax), diplopia, or sudden visual loss, these are ophthalmologic emergencies requiring immediate action. Also inquire about limb claudication (arms or legs) and symptoms of polymyalgia rheumatica (morning stiffness in shoulders, neck, hips).
  • •Examine the temporal arteries for tenderness, nodularity, thickening, or pulselessness; a firm, beaded cord is pathognomonic but often absent. Check for blood pressure asymmetry >10 mm Hg (suggests large-artery stenosis), and perform ophthalmologic examination (afferent pupillary defect, optic disc edema, pallor) if visual symptoms are present.
  • •Order urgent laboratory studies: ESR, CRP, complete blood count, and comprehensive metabolic panel. ESR ≥50 mm/hr or CRP ≥10 mg/L supports the diagnosis but up to 10% of biopsy-proven GCA patients have normal levels.
  • •Perform high-resolution ultrasound of the temporal and axillary arteries as the first-line imaging test (EULAR 2023 recommendation). The halo sign, a non-compressible, hypoechoic, concentric wall thickening, has pooled sensitivity 88% and specificity 96% for GCA. Scanning should occur within days of starting glucocorticoids, as the halo sign resolves within 2-4 weeks of therapy.
  • •If ultrasound is equivocal or negative but clinical suspicion remains high, proceed to temporal artery biopsy (TAB) or MRI of the scalp arteries. TAB has a sensitivity of only ~69% (giant cells, fragmentation of internal elastic lamina, mononuclear infiltration); a negative biopsy does not rule out GCA.
  • •Consider [18F]-FDG-PET/CT when large-vessel involvement is suspected or cranial imaging is equivocal. The GAPS study reported sensitivity 71% and specificity 91% against clinical diagnosis, with a negative predictive value of 98%. FDG-PET also detects incidental infections or malignancies and aortitis.
  • •Apply the 2022 ACR/EULAR classification criteria to standardize diagnosis: age ≥50 mandatory; positive TAB or halo sign (+5), ESR ≥50 or CRP ≥10 (+3), sudden visual loss (+3), morning stiffness in shoulders/neck (+2), jaw or tongue claudication (+2), new temporal headache (+2), scalp tenderness (+2), temporal artery abnormality on exam (+2), bilateral axillary involvement on imaging (+2), FDG-PET activity throughout aorta (+2). Score ≥6 classifies as GCA.
  • •Also consider alternative diagnoses: ANCA-associated vasculitis (check ANCA if atypical features like renal, pulmonary, or ENT involvement), VEXAS syndrome (consider in older men with treatment-refractory GCA-like symptoms, cytopenias, and bone marrow vacuoles), and other causes of headache or systemic inflammation.
  • •Assess disease activity using clinical examination and inflammatory markers. The OMERACT GCA Ultrasonography Score (OGUS) quantifies intima-media thickness and predicts relapse risk (IRR 1.85 per 1-point increase). For patients on tocilizumab, note that CRP normalizes rapidly regardless of disease activity, so clinical assessment is paramount.

Management

  • •For patients without visual loss or organ-threatening features, start 40-60 mg/day orally or IV equivalent. For patients with acute visual loss or amaurosis fugax, give IV 1 g/day for 3 days, followed by high-dose oral taper. Do not delay therapy for diagnostic tests, biopsy or imaging can be performed within 1-2 weeks of starting glucocorticoids without loss of diagnostic sensitivity.
  • •Begin glucocorticoid taper once the flare is controlled. The ACR 2021 guideline recommends a taper over 6-12 months; a 26-week taper is feasible when a steroid-sparing agent is used. Monitor for glucocorticoid adverse effects: blood glucose, blood pressure, bone density, and infection risk.
  • •Add a glucocorticoid-sparing agent in patients with refractory or relapsing disease, or those at high risk for glucocorticoid toxicity. First-line options: 162 mg SC weekly (or 8 mg/kg IV monthly) plus a 26-week prednisone taper, or 15-25 mg PO/SC weekly.
  • •Tocilizumab: In the GiACTA trial, sustained glucocorticoid-free remission at week 52 was 56% (weekly) vs 14% (placebo+26-week taper), NNT = 2.4. Continue for at least 12 months; after discontinuation, approximately 50% will relapse within 1-2 years. Monitor for neutropenia (hold if ANC <1000/μL), elevated transaminases (hold if >3× ULN), and hyperlipidemia (check lipid panel at 4-8 weeks, then every 6-12 months).
  • •Methotrexate: Modest glucocorticoid-sparing effect; less effective than tocilizumab. Monitor for toxicity, especially in elderly patients on diuretics, PPIs, or with low eGFR. Start with folic acid 1 mg daily to reduce toxicity.
  • •Alternative second-line agents: 15 mg PO daily with 26-week taper (SELECT-GCA: sustained remission 46.4% vs 29.0%, NNT 5.7; use with caution in patients with high cardiovascular risk); 10 mg/kg IV on days 1, 15, 29, then monthly (median remission duration 9.9 vs 3.9 months); 150 mg SC every 2 weeks (investigational, reduced flare risk by 62% in phase 2).
  • •Do not use anti-TNF agents (infliximab, adalimumab, etanercept), they have shown no benefit in GCA. Do not routinely use antiplatelet or anticoagulant therapy for GCA itself unless indicated for other reasons. Do not rely on CRP/ESR alone to guide therapy in tocilizumab-treated patients (92% of flares occur with normal CRP).
  • •Monitor for disease-driven complications: aortic aneurysm (2-fold risk; 4.5-fold faster growth than degenerative aneurysms), perform CT or MR angiography of thoracic aorta at diagnosis and at 5 years. Cerebrovascular events (3.96% of patients, predominantly vertebrobasilar), manage cardiovascular risk factors aggressively.
  • •Prevent glucocorticoid-induced osteoporosis: all patients starting ≥7.5 mg/day prednisolone for ≥3 months should receive calcium (1000-1200 mg/day), vitamin D (800 IU/day), and a bisphosphonate (alendronate 70 mg weekly or zoledronic acid 5 mg annually).
  • •Ensure vaccination: recombinant zoster vaccine (before or during glucocorticoid tapering, ideally ≥2 weeks before immunosuppression), annual influenza, pneumococcal, and SARS-CoV-2 boosters. Live-attenuated vaccines are contraindicated during high-dose immunosuppression.
  • •Refer to rheumatology urgently for all suspected GCA. For acute visual loss, refer to ophthalmology same day. Consider multidisciplinary care for large-vessel involvement (vascular surgery, cardiology). Discharge criteria: patient stable on therapy, no acute visual loss, and clear plan for glucocorticoid taper and monitoring.

Board Review — High Yield

  • •Jaw claudication, the single strongest clinical predictor of GCA; positive likelihood ratio >10.
  • •Halo sign on ultrasound, non-compressible, hypoechoic, concentric wall thickening of temporal/axillary arteries; sensitivity 88%, specificity 96%.
  • •2022 ACR/EULAR criteria, age ≥50 mandatory; score ≥6 = classify as GCA; positive TAB or halo sign = +5 points.
  • •IL-6/Th17 vs IL-12/Th1 axis, the former is glucocorticoid-sensitive (systemic inflammation), the latter is steroid-resistant (vessel wall damage); explains why tocilizumab targets IL-6 but relapses may occur via Th1 pathway.
  • •GiACTA trial, tocilizumab 162 mg SC weekly + 26-week prednisone taper: 56% sustained glucocorticoid-free remission at week 52 vs 14% with placebo; NNT 2.4.
  • •Aortic aneurysm risk, 2-fold increase in GCA; 4.5-fold faster growth than degenerative aneurysms; CT/MR angiography at diagnosis and 5 years.
  • •Tocilizumab safety, neutropenia, transaminitis, hyperlipidemia; monitor ANC, ALT/AST, lipids; hold if ANC <1000/μL or ALT >3× ULN.
  • •What NOT to do, do not use anti-TNF agents; do not use antiplatelet/anticoagulation for GCA alone; do not rely on CRP/ESR in tocilizumab-treated patients.
  • •VEXAS syndrome, consider in older men with treatment-refractory GCA-like symptoms, cytopenias, and bone marrow vacuoles (somatic UBA1 mutation).
  • •Vertebrobasilar stroke, 62.3% of cerebrovascular events in GCA; mortality doubled in patients with CVA (18% vs 8.8%).

Deep Dive — Evidence Details

References

  1. [1]

    Patel NJ, Tozzo V, Higgins JM et al.. “The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36383175 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  2. [2]

    Saraux A, Le Henaff C, Dernis E et al.. “Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.” The Lancet. Rheumatology (2023). PMID: 38251563 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  3. [3]

    Matza MA, Fernandes AD, Stone JH et al.. “Ustekinumab for the Treatment of Giant Cell Arteritis.” Arthritis care & research (2021). PMID: 32248659 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  4. [4]

    Prieto-González S, Depetris M, García-Martínez A et al.. “Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.” Annals of the rheumatic diseases (2014). PMID: 24665112 ↗

    L3CASE_CONTROLCited in: Definition, Classification & Nomenclature
  5. [5]

    Rubenstein E, Maldini C, Gonzalez-Chiappe S et al.. “Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis.” Rheumatology (Oxford, England) (2020). PMID: 31529073 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  6. [6]

    Kermani TA, Ytterberg SR, Warrington KJ. “Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.” Arthritis care & research (2011). PMID: 21240966 ↗

    L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  7. [7]

    Muratore F, Kermani TA, Crowson CS et al.. “Large-vessel giant cell arteritis: a cohort study.” Rheumatology (Oxford, England) (2014). PMID: 25193809 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Prognosis & Natural History
  8. [8]

    Therkildsen P, de Thurah A, Nielsen BD et al.. “Increased risk of thoracic aortic complications among patients with giant cell arteritis: a nationwide, population-based cohort study.” Rheumatology (Oxford, England) (2022). PMID: 34918058 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  9. [9]

    Sanchez-Alvarez C, Bond M, Soowamber M et al.. “Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force.” RMD open (2023). PMID: 37349123 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  10. [10]

    Ponte C, Grayson PC, Robson JC et al.. “2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.” Annals of the rheumatic diseases (2022). PMID: 36351706 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  11. [11]

    Bauer CJ, Chrysidis S, Dejaco C et al.. “Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-US-AI project.” Annals of the rheumatic diseases (2025). PMID: 40514330 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  12. [12]

    De Miguel E, Karalilova R, Macchioni P et al.. “Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.” Annals of the rheumatic diseases (2024). PMID: 37932008 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease
  13. [13]

    Soowamber ML, Bond M, Touma Z et al.. “A glossary of signs and symptoms of giant cell arteritis.” Annals of the rheumatic diseases (2025). PMID: 40731213 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation
  14. [14]

    Mukhtyar CB, Beadsmoore C, Coath FL et al.. “Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020.” Annals of the rheumatic diseases (2023). PMID: 37399329 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature
  15. [15]

    Grayson PC, Maksimowicz-McKinnon K, Clark TM et al.. “Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis.” Annals of the rheumatic diseases (2012). PMID: 22328740 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  16. [16]

    Ponte C, Grayson PC, Robson JC et al.. “2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36350123 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  17. [17]

    England BR, Mikuls TR, Xie F et al.. “Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28853238 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prevention, Screening & Surveillance
  18. [18]

    Saadoun D, Garrido M, Comarmond C et al.. “Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25604824 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
  19. [19]

    Petri H, Nevitt A, Sarsour K et al.. “Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities.” Arthritis care & research (2015). PMID: 25132663 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  20. [20]

    Barra L, Pope JE, Pequeno P et al.. “Increased Mortality for Individuals With Giant Cell Arteritis: A Population-Based Study.” Arthritis care & research (2022). PMID: 33544963 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prognosis & Natural History
  21. [21]

    Gribbons KB, Ponte C, Carette S et al.. “Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis.” Arthritis care & research (2020). PMID: 31444857 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  22. [22]

    Muratore F, Cavazza A, Boiardi L et al.. “Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study.” Arthritis care & research (2016). PMID: 26415044 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  23. [23]

    Bosch P, Espigol-Frigolé G, Cid MC et al.. “Cranial involvement in giant cell arteritis.” The Lancet. Rheumatology (2024). PMID: 38574747 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  24. [24]

    Cacoub P, Vieira M, Langford CA et al.. “Large-vessel vasculitis.” Lancet (London, England) (2025). PMID: 40939604 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  25. [25]

    Kermani TA, Warrington KJ. “Polymyalgia rheumatica.” Lancet (London, England) (2012). PMID: 23051717 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prognosis & Natural History
  26. [26]

    Schmidt WA, Dasgupta B, Sloane J et al.. “A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.” Arthritis research & therapy (2023). PMID: 37840134 ↗

    L1RCTCited in: Definition, Classification & Nomenclature
  27. [27]

    Pouncey AL, Yeldham G, Magan T et al.. “Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis.” The Cochrane database of systematic reviews (2024). PMID: 38323659 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  28. [28]

    Penet T, Lambert M, Baillet C et al.. “Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis.” Arthritis research & therapy (2023). PMID: 37420252 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  29. [29]

    Shah S, Rao S, Mackie SL et al.. “A history of polymyalgia rheumatica: a narrative review.” Rheumatology (Oxford, England) (2025). PMID: 39412500 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  30. [30]

    Fernández-Lozano D, Domínguez-Álvaro M, Narváez J et al.. “Sex differences among patients with giant cell arteritis: insights from the Spanish ARTESER Registry.” Rheumatology (Oxford, England) (2026). PMID: 41452742 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  31. [31]

    Chanson N, Galvagni A, Ramos-Casals M et al.. “Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course.” Rheumatology (Oxford, England) (2025). PMID: 39714261 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
  32. [32]

    Wiberg F, Naderi N, Mohammad AJ et al.. “Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes.” Rheumatology (Oxford, England) (2021). PMID: 33871583 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Pregnancy & Fertility
  33. [33]

    Cutolo M, Soldano S, Smith V et al.. “Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2025). PMID: 40721670 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  34. [34]

    Fernández-Guitián R, Royuela A, Tornero-Romero F et al.. “Methylprednisolone pulses are associated with faster remission in Giant Cell Arteritis: a multicentre inception cohort study.” Arthritis research & therapy (2026). PMID: 41862996 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  35. [35]

    Dhrif O, Caudron C, Parreau S et al.. “Stroke characteristics in giant cell arteritis and Takayasu arteritis: A multicenter retrospective cohort study of 108 patients.” Seminars in arthritis and rheumatism (2026). PMID: 41702324 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  36. [36]

    Fernández-Lozano D, Hernández-Rodríguez I, Narvaez J et al.. “Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register.” RMD open (2024). PMID: 38531620 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  37. [37]

    van Nieuwland M, van Bon L, Vermeer M et al.. “External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic.” RMD open (2023). PMID: 37507207 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  38. [38]

    Molina-Collada J, Castrejón I, Monjo I et al.. “Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care.” RMD open (2023). PMID: 37094980 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  39. [39]

    Osiowski A, Osiowski M, Stolarz K et al.. “Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis.” Rheumatology international (2025). PMID: 39932568 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  40. [40]

    Borrego-Yaniz G, Ortiz-Fernández L, Madrid-Paredes A et al.. “Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study.” The Lancet. Rheumatology (2024). PMID: 38734017 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  41. [41]

    Iwasaki T, Watanabe R, Zhang H et al.. “Identification of the VLDLR locus associated with giant cell arteritis and the possible causal role of low-density lipoprotein cholesterol in its pathogenesis.” Rheumatology (Oxford, England) (2024). PMID: 38317496 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  42. [42]

    Kastrati K, Aletaha D, Burmester GR et al.. “A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.” RMD open (2022). PMID: 36260501 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  43. [43]

    Aletaha D, Kerschbaumer A, Kastrati K et al.. “Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.” Annals of the rheumatic diseases (2022). PMID: 35953263 ↗

    L1OTHERCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Prevention, Screening & Surveillance
  44. [44]

    Karabayas M, Ibrahim HE, Roelofs AJ et al.. “Vascular disease persistence in giant cell arteritis: are stromal cells neglected?” Annals of the rheumatic diseases (2024). PMID: 38684323 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  45. [45]

    Corbera-Bellalta M, Kamberovic F, Alba-Rovira R et al.. “The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis.” Annals of the rheumatic diseases (2025). PMID: 40074597 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  46. [46]

    Miyabe C, Miyabe Y, Strle K et al.. “An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.” Annals of the rheumatic diseases (2016). PMID: 27927642 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  47. [47]

    Ciccia F, Macaluso F, Mauro D et al.. “New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?” The Lancet. Rheumatology (2021). PMID: 38287633 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  48. [48]

    Salvarani C, Cantini F, Hunder GG. “Polymyalgia rheumatica and giant-cell arteritis.” Lancet (London, England) (2008). PMID: 18640460 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  49. [49]

    Mehrpoor G, Gargari OK, Khorasani S et al.. “Varicella Zoster Virus in Giant Cell Arteritis: Evidence From a Systematic Review and Meta-Analytic Synthesis.” Reviews in medical virology (2026). PMID: 41450088 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  50. [50]

    Neiroukh D, Hajdarpasic A, Ayhan C et al.. “Gut Microbial Taxonomy and Its Role as a Biomarker in Aortic Diseases: A Systematic Review and Future Perspectives.” Journal of clinical medicine (2024). PMID: 39598083 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism
  51. [51]

    Schäfer VS, Brossart P, Warrington KJ et al.. “The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature review.” Autoimmunity reviews (2023). PMID: 36990133 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism
  52. [52]

    Mirouse A, Cacoub P, Saadoun D. “Regulatory T cells and systemic vasculitis.” Current opinion in rheumatology (2022). PMID: 36508306 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism
  53. [53]

    O'Neill L, Molloy ES. “The role of toll like receptors in giant cell arteritis.” Rheumatology (Oxford, England) (2016). PMID: 26893518 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  54. [54]

    Cid MC, Ríos-Garcés R, Terrades-García N et al.. “Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.” Rheumatology (Oxford, England) (2020). PMID: 32348525 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  55. [55]

    Terrades-Garcia N, Cid MC. “Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved.” Rheumatology (Oxford, England) (2018). PMID: 29982777 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  56. [56]

    Dejaco C, Duftner C, Buttgereit F et al.. “The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.” Rheumatology (Oxford, England) (2017). PMID: 27481272 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  57. [57]

    Cantoni E, Merelli I, Stefanoni D et al.. “Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production.” Rheumatology (Oxford, England) (2023). PMID: 36802235 ↗

    L4OTHERCited in: Pathophysiology & Mechanism
  58. [58]

    Keser G, Aksu K, Direskeneli H. “Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited.” Rheumatology (Oxford, England) (2018). PMID: 28968895 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  59. [59]

    Choy EH, De Benedetti F, Takeuchi T et al.. “Translating IL-6 biology into effective treatments.” Nature reviews. Rheumatology (2020). PMID: 32327746 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  60. [60]

    Dejaco C, Brouwer E, Mason JC et al.. “Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.” Nature reviews. Rheumatology (2017). PMID: 28905861 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  61. [61]

    Muratore F, Warrington KJ, Dejaco C et al.. “Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.” Nature reviews. Rheumatology (2026). PMID: 42162376 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
  62. [62]

    Weyand CM, Goronzy JJ. “Immune mechanisms in medium and large-vessel vasculitis.” Nature reviews. Rheumatology (2013). PMID: 24189842 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  63. [63]

    Sandovici M, van der Geest N, van Sleen Y et al.. “Need and value of targeted immunosuppressive therapy in giant cell arteritis.” RMD open (2022). PMID: 35149602 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  64. [64]

    Sandovici M, van der Geest KSM, Reitsema RD et al.. “Challenges and Future Trends in Large Vessel Vasculitis.” Circulation (2026). PMID: 42330100 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  65. [65]

    Cayrou C, Gallet F, Ly K et al.. “Unraveling giant cell arteritis: From immunopathology to emerging targeted therapies (2026 update).” Autoimmunity reviews (2026). PMID: 42288301 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Fertility
  66. [66]

    Unizony SH, Bao M, Han J et al.. “Treatment failure in giant cell arteritis.” Annals of the rheumatic diseases (2021). PMID: 34049857 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  67. [67]

    Mackie SL, Hensor EM, Morgan AW et al.. “Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis.” Annals of the rheumatic diseases (2012). PMID: 23264356 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  68. [68]

    Venhoff N, Schmidt WA, Bergner R et al.. “Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet. Rheumatology (2023). PMID: 38251601 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment, Prognosis & Natural History
  69. [69]

    Monti S, Ponte C, Schäfer VS et al.. “The giant cell arteritis (GCA) ultrasound score (OGUS) at diagnosis and after initial treatment predicts future relapses in GCA patients: results of a multicentre prospective study.” Annals of the rheumatic diseases (2025). PMID: 39919971 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  70. [70]

    Kermani TA, Warrington KJ, Crowson CS et al.. “Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.” Annals of the rheumatic diseases (2012). PMID: 23253927 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance
  71. [71]

    Schmidt J, Smail A, Roche B et al.. “Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26815885 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  72. [72]

    Mainbourg S, Addario A, Samson M et al.. “Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.” Arthritis care & research (2020). PMID: 30951256 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  73. [73]

    Udayakumar PD, Chandran AK, Crowson CS et al.. “Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study.” Arthritis care & research (2015). PMID: 25074472 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History, Prevention, Screening & Surveillance
  74. [74]

    Kermani TA, Schäfer VS, Crowson CS et al.. “Malignancy risk in patients with giant cell arteritis: a population-based cohort study.” Arthritis care & research (2010). PMID: 20191512 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  75. [75]

    Goulabchand R, Qian AS, Nguyen NH et al.. “Burden, Causes, and Outcomes of Hospitalization in Patients With Giant Cell Arteritis: A US National Cohort Study.” Arthritis care & research (2023). PMID: 36576029 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  76. [76]

    Durand M, Thomas SL. “Incidence of infections in patients with giant cell arteritis: a cohort study.” Arthritis care & research (2012). PMID: 22184094 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  77. [77]

    Rhee RL, Grayson PC, Merkel PA et al.. “Infections and the risk of incident giant cell arteritis: a population-based, case-control study.” Annals of the rheumatic diseases (2016). PMID: 27895041 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  78. [78]

    Sattui SE, Conway R, Putman MS et al.. “Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study.” The Lancet. Rheumatology (2021). PMID: 34778843 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
  79. [79]

    Barde F, Pacoureau L, Elbaz A et al.. “Association between cardiovascular risk factors and the occurrence of giant cell arteritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2025). PMID: 40127188 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  80. [80]

    Lai LYH, Harris E, West RM et al.. “Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis.” RMD open (2018). PMID: 29531778 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease
  81. [81]

    Gutierrez-Rodrigues F, Wells KV, Jones AI et al.. “Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.” Annals of the rheumatic diseases (2024). PMID: 38049983 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  82. [82]

    Borrego-Yaniz G, Fuentes-Moreno V, Ortiz-Fernández L et al.. “Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.” Annals of the rheumatic diseases (2026). PMID: 42399125 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  83. [83]

    Gribbons KB, Ponte C, Craven A et al.. “Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 31729185 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  84. [84]

    Maalouf G, Arnould B, Espitia O et al.. “Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41728983 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  85. [85]

    Martínez-Gutiérrez L, Borrego-Yaniz G, Hernández-Rodríguez J et al.. “Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 42045811 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  86. [86]

    Unizony S, Lu N, Tomasson G et al.. “Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28029234 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease
  87. [87]

    Chakravarti R, Gupta K, Swain M et al.. “14-3-3 in Thoracic Aortic Aneurysms: Identification of a Novel Autoantigen in Large Vessel Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25917817 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  88. [88]

    Hemmig AK, Aschwanden M, Seiler S et al.. “Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study.” RMD open (2023). PMID: 36635003 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  89. [89]

    Andersen JB, Myklebust G, Haugeberg G et al.. “Incidence Trends and Mortality of Giant Cell Arteritis in Southern Norway.” Arthritis care & research (2021). PMID: 31909871 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  90. [90]

    Muratore F, Kermani TA, Crowson CS et al.. “Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?” Arthritis care & research (2018). PMID: 29266882 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  91. [91]

    Saadoun D, Vieira M, Vautier M et al.. “SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study.” The Lancet. Rheumatology (2021). PMID: 33942031 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  92. [92]

    Dhivagaran T, Butt FR, Nasri D et al.. “Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis.” Eye (London, England) (2026). PMID: 41572017 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  93. [93]

    Martínez-Gutiérrez L, Rodriguez-Martin I, Borrego-Yaniz G et al.. “Cross-Trait Meta-Analysis Reveals a Genetic Link between Inflammation and Aging in Giant Cell Arteritis.” Aging and disease (2025). PMID: 40901985 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
  94. [94]

    Sullivan MM, Mead-Harvey C, Sartori-Valinotti JC et al.. “Vasculitis associated with VEXAS syndrome.” Rheumatology (Oxford, England) (2025). PMID: 39392442 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  95. [95]

    Martín-Gutiérrez A, Molina-Collada J, Domínguez-Álvaro M et al.. “Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry.” Rheumatology (Oxford, England) (2025). PMID: 39918980 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  96. [96]

    Barra L, Pope JE, Pequeno P et al.. “Incidence and prevalence of giant cell arteritis in Ontario, Canada.” Rheumatology (Oxford, England) (2020). PMID: 32249899 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  97. [97]

    Greigert H, Mounier M, Arnould L et al.. “Heamatological malignancies in giant cell arteritis: a French population-based study.” Rheumatology (Oxford, England) (2021). PMID: 33792672 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  98. [98]

    Narváez J, Domínguez-Álvaro M, Hernández-Rodríguez I et al.. “Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry.” Rheumatology (Oxford, England) (2025). PMID: 40343487 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  99. [99]

    Watts RA, Hatemi G, Burns JC et al.. “Global epidemiology of vasculitis.” Nature reviews. Rheumatology (2021). PMID: 34853411 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  100. [100]

    Soriano A, Muratore F, Pipitone N et al.. “Visual loss and other cranial ischaemic complications in giant cell arteritis.” Nature reviews. Rheumatology (2017). PMID: 28680132 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  101. [101]

    Nitzan I, Shemesh N, Kubovsky S et al.. “Incidence of Giant Cell Arteritis Following Herpes Zoster Ophthalmicus: A Multicenter Retrospective Cohort Study.” American journal of ophthalmology (2025). PMID: 40414592 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  102. [102]

    Kumar C, Kuhn M, Herrmann K et al.. “Severe methotrexate toxicity in elderly patients under diuretics.” RMD open (2024). PMID: 38176739 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  103. [103]

    Guedon AF, Ouafdi A, Belfeki N et al.. “Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis.” RMD open (2024). PMID: 39658053 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  104. [104]

    Jud P, Hafner F, Meinitzer A et al.. “Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis.” RMD open (2023). PMID: 37657846 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  105. [105]

    Elfishawi MM, Kaymakci MS, J Achenbach S et al.. “Reappraisal of large artery involvement in giant cell arteritis: a population-based cohort over 70 years.” RMD open (2024). PMID: 38331471 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  106. [106]

    Besutti G, Marvisi C, Mancuso P et al.. “Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: a matched cross-sectional study.” RMD open (2023). PMID: 37640517 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  107. [107]

    Zhu LM, Mendel A, Ross C et al.. “The effectiveness and safety of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis.” Rheumatology advances in practice (2025). PMID: 41323363 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  108. [108]

    Dhrif O, Lahmar W, Achour TB et al.. “Seasonality and latitude as linked environmental factors in giant cell arteritis incidence: a systematic review and meta-analysis.” Rheumatology international (2025). PMID: 41128917 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  109. [109]

    Horiuchi S, Kudo Y, Kawano K et al.. “Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database.” Arthritis research & therapy (2026). PMID: 41764518 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors
  110. [110]

    Sørensen MER, Lindhardt Petersen SS, Overgaard AL et al.. “The impact of interleukin-6 receptor inhibitors on risk of diabetes mellitus in patients with giant cell arteritis: a cohort study.” Rheumatology international (2026). PMID: 42362950 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  111. [111]

    Lakrafi Y, Moudatir M, Echchilali K et al.. “Treatment-resistant arterial hypertension revealing giant cell arteritis: A case report.” The American journal of medicine (2026). PMID: 41791692 ↗

    L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  112. [112]

    Ortiz-Fernández L, Carmona FD, López-Mejías R et al.. “Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.” Annals of the rheumatic diseases (2018). PMID: 29374629 ↗

    L3SR_OBSCited in: Clinical Presentation
  113. [113]

    Delaval L, Samson M, Schein F et al.. “Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A Case-Control Study.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32951354 ↗

    L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  114. [114]

    Emmi G, Bagni G, Lastraioli E et al.. “A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome.” Annals of the rheumatic diseases (2021). PMID: 34844932 ↗

    L3OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance
  115. [115]

    Veroutis D, Argyropoulou OD, Goules AV et al.. “Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways.” Annals of the rheumatic diseases (2024). PMID: 38050005 ↗

    L3OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  116. [116]

    Ehlers L, Askling J, Bijlsma HW et al.. “2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.” Annals of the rheumatic diseases (2019). PMID: 30898837 ↗

    L1REVIEW_NARRATIVECited in: Clinical Presentation
  117. [117]

    Cowley S, Harkins P, Kirby C et al.. “Should all patients with polymyalgia rheumatica have a vascular ultrasound assessment?” Annals of the rheumatic diseases (2024). PMID: 38553044 ↗

    L5OTHERCited in: Clinical Presentation, Prevention, Screening & Surveillance
  118. [118]

    Robinette ML, Weeks LD, Kramer RJ et al.. “Association of Somatic TET2 Mutations With Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37909388 ↗

    L2OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  119. [119]

    Alba MA, Unizony S, Warrington KJ et al.. “Management of Relapses in Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39711085 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  120. [120]

    Jiemy WF, van Sleen Y, Graver JC et al.. “Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37057491 ↗

    L4OTHERCited in: Clinical Presentation
  121. [121]

    Clifford AH, Arafat A, Idrees JJ et al.. “Outcomes Among 196 Patients With Noninfectious Proximal Aortitis.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30730604 ↗

    L4OTHERCited in: Clinical Presentation
  122. [122]

    Desbois AC, Régnier P, Quiniou V et al.. “Specific Follicular Helper T Cell Signature in Takayasu Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33538119 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  123. [123]

    Maughan RT, Macdonald-Dunlop E, Haroon-Rashid L et al.. “Proteomic Profiling of the Large-Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39817309 ↗

    L3OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  124. [124]

    Putman MS, Gribbons KB, Ponte C et al.. “Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis.” Arthritis care & research (2022). PMID: 33338326 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  125. [125]

    Sebastian A, van der Geest KSM, Tomelleri A et al.. “Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study.” The Lancet. Rheumatology (2024). PMID: 38554720 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  126. [126]

    Beck DB, Ferrada MA, Sikora KA et al.. “Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.” The New England journal of medicine (2020). PMID: 33108101 ↗

    L4OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  127. [127]

    Chen RY, Mandzia J, Barra L. “Cognitive impairment and other neuropsychiatric manifestations in patients with primary vasculitis: a systematic review.” Seminars in arthritis and rheumatism (2025). PMID: 40784139 ↗

    L2SR_OBSCited in: Clinical Presentation
  128. [128]

    Junek ML, Okaj I, Patel S et al.. “Multivariable Models to Predict a Diagnosis of Giant Cell Arteritis: Systematic Review and Metaanalysis.” The Journal of rheumatology (2025). PMID: 40592550 ↗

    L2SR_OBSCited in: Clinical Presentation
  129. [129]

    Vodopivec I, Rizzo JF. “Ophthalmic manifestations of giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29986083 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  130. [130]

    Blanco R, Aldasoro V, Maiz O et al.. “Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases.” Rheumatology (Oxford, England) (2025). PMID: 39658241 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  131. [131]

    Kern D, Bley TA, Riedling L et al.. “Vascular MRI also depicts musculoskeletal manifestations in giant-cell arteritis-polymyalgia rheumatica spectrum disease patients.” Rheumatology (Oxford, England) (2025). PMID: 40131396 ↗

    L4OTHERCited in: Clinical Presentation
  132. [132]

    Kermani TA, Sreih AG, Cuthbertson D et al.. “Evaluation of damage in giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29112740 ↗

    L2OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  133. [133]

    Petzinna SM, Burg LC, Bauer CJ et al.. “Transorbital ultrasound in the diagnosis of giant cell arteritis.” Rheumatology (Oxford, England) (2024). PMID: 38759118 ↗

    L2OTHERCited in: Clinical Presentation
  134. [134]

    Salvarani C, Pipitone N, Versari A et al.. “Clinical features of polymyalgia rheumatica and giant cell arteritis.” Nature reviews. Rheumatology (2012). PMID: 22825731 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  135. [135]

    Molina-Collada J, Castrejón I, Monjo-Henry I et al.. “Impact of ultrasound limitation to assess aortitis in patients with giant cell arteritis: comparative study with FDG-PET/CT.” RMD open (2023). PMID: 37597848 ↗

    L4OTHERCited in: Clinical Presentation
  136. [136]

    Azoyan L, Bonjour M, Steichen O. “Diagnostic Accuracy of Clinical Findings for Takayasu Arteritis: A Rapid Review and Meta-Analysis.” International journal of vascular medicine (2025). PMID: 40963697 ↗

    L2SR_OBSCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
  137. [137]

    Kawamoto T, Ogasawara M, Nojiri S et al.. “Clinical characteristics of giant cell arteritis with ocular involvement: A single-centre retrospective study.” Modern rheumatology (2026). PMID: 41714188 ↗

    L3COHORTCited in: Clinical Presentation
  138. [138]

    Shahid F, Farooq H, Abeer H et al.. “The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.” Clinical medicine insights. Arthritis and musculoskeletal disorders (2026). PMID: 41567360 ↗

    L4SR_OBSCited in: Clinical Presentation
  139. [139]

    Rubinsztajn A, Parreau S, Sailler L et al.. “Characteristics of patients with major relapse in giant cell arteritis: a multicenter case-control study.” Clinical rheumatology (2025). PMID: 41310094 ↗

    L3CASE_CONTROLCited in: Clinical Presentation
  140. [140]

    Dejaco C, Ramiro S, Bond M et al.. “EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.” Annals of the rheumatic diseases (2024). PMID: 37550004 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  141. [141]

    Maz M, Chung SA, Abril A et al.. “2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.” Arthritis care & research (2021). PMID: 34235871 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
  142. [142]

    Makhzoum JP, Cid MC, Samson M et al.. “A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis.” Annals of the rheumatic diseases (2026). PMID: 41688258 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  143. [143]

    Dejaco C, Ramiro S, Touma Z et al.. “What is a response in randomised controlled trials in giant cell arteritis?” Annals of the rheumatic diseases (2023). PMID: 36801812 ↗

    L5RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  144. [144]

    Stone JH, Tuckwell K, Dimonaco S et al.. “Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30835950 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  145. [145]

    Dejaco C, Ramiro S, Duftner C et al.. “EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.” Annals of the rheumatic diseases (2018). PMID: 29358285 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  146. [146]

    Villiger PM, Adler S, Kuchen S et al.. “Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2016). PMID: 26952547 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  147. [147]

    Blockmans D, Penn SK, Setty AR et al.. “A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.” The New England journal of medicine (2025). PMID: 40174237 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  148. [148]

    Rhéaume M, Rebello R, Pagnoux C et al.. “High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 27483045 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  149. [149]

    Stone JH, Spotswood H, Unizony SH et al.. “New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.” Rheumatology (Oxford, England) (2022). PMID: 34718434 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  150. [150]

    Diamantopoulos AP, Haugeberg G, Hetland H et al.. “Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series.” Arthritis care & research (2014). PMID: 24106211 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  151. [151]

    Bosch P, Bond M, Dejaco C et al.. “Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations.” RMD open (2023). PMID: 37620113 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  152. [152]

    Dejaco C, Ponte C, Monti S et al.. “The provisional OMERACT ultrasonography score for giant cell arteritis.” Annals of the rheumatic diseases (2022). PMID: 36600183 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  153. [153]

    Koster MJ, Crowson CS, Giblon RE et al.. “Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.” Annals of the rheumatic diseases (2022). PMID: 35190385 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  154. [154]

    Segarra M, García-Martínez A, Sánchez M et al.. “Gelatinase expression and proteolytic activity in giant-cell arteritis.” Annals of the rheumatic diseases (2007). PMID: 17502363 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  155. [155]

    Brkic A, Terslev L, Møller Døhn U et al.. “Clinical Applicability of Ultrasound in Systemic Large Vessel Vasculitides.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31309732 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  156. [156]

    van der Geest KSM, Sandovici M, van Sleen Y et al.. “Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29648680 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  157. [157]

    Quinn KA, Ahlman MA, Alessi HD et al.. “Association of 18 F-Fluorodeoxyglucose-Positron Emission Tomography Activity With Angiographic Progression of Disease in Large Vessel Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35792044 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  158. [158]

    Sammel AM, Hsiao E, Schembri G et al.. “Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double-Blind, Cross-Sectional Study.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30848549 ↗

    L1OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  159. [159]

    Unizony S, Arias-Urdaneta L, Miloslavsky E et al.. “Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.” Arthritis care & research (2012). PMID: 22674883 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  160. [160]

    Rimland CA, Quinn KA, Rosenblum JS et al.. “Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments.” Arthritis care & research (2020). PMID: 31785185 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  161. [161]

    Turkiewicz A, Stamatis P, Mohammad AJ. “Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case-control study.” RMD open (2020). PMID: 32792416 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  162. [162]

    van der Geest KSM, Sandovici M, Bley TA et al.. “Large vessel giant cell arteritis.” The Lancet. Rheumatology (2024). PMID: 38574745 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  163. [163]

    Yates M, Davies C, MacGregor AJ. “Improving polymyalgia rheumatica care: considerations for routine vascular ultrasound in clinical practice.” The Lancet. Rheumatology (2025). PMID: 40112839 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  164. [164]

    Nettleton E, Carlson K, Putman M. “The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumatica.” The Lancet. Rheumatology (2024). PMID: 39341221 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
  165. [165]

    Espígol-Frigolé G, Dejaco C, Mackie SL et al.. “Polymyalgia rheumatica.” Lancet (London, England) (2023). PMID: 37832573 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  166. [166]

    González-Gay MA, Matteson EL, Castañeda S. “Polymyalgia rheumatica.” Lancet (London, England) (2017). PMID: 28774422 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  167. [167]

    Dejaco C, Matteson EL. “Polymyalgia Rheumatica.” The New England journal of medicine (2026). PMID: 41812194 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  168. [168]

    Stone JH, Venhoff N, Buttgereit F et al.. “Secukinumab for Giant Cell Arteritis.” NEJM evidence (2026). PMID: 42234457 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  169. [169]

    Alibaz-Oner F, Kara M, Esatoglu SN et al.. “Turkish Society for Rheumatology recommendations for the diagnosis, follow-up and management of giant cell arteritis.” Clinical and experimental rheumatology (2026). PMID: 41930660 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  170. [170]

    Ponte C, Martins-Martinho J, Luqmani RA. “Diagnosis of giant cell arteritis.” Rheumatology (Oxford, England) (2020). PMID: 32348512 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  171. [171]

    Narváez J, Domínguez M, Galíndez E et al.. “Sustained drug-free remission in giant cell arteritis.” Rheumatology (Oxford, England) (2025). PMID: 39589919 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  172. [172]

    Coath FL, Mukhtyar C. “Ultrasonography in the diagnosis and follow-up of giant cell arteritis.” Rheumatology (Oxford, England) (2021). PMID: 33599253 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  173. [173]

    Schmidt WA. “Ultrasound in the diagnosis and management of giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29982780 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  174. [174]

    Koster MJ, Matteson EL, Warrington KJ. “Large-vessel giant cell arteritis: diagnosis, monitoring and management.” Rheumatology (Oxford, England) (2018). PMID: 29982778 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  175. [175]

    Junek ML, Riaz S, Garner S et al.. “Added diagnostic yield of temporal artery magnetic resonance angiography in the evaluation of giant cell arteritis.” Rheumatology (Oxford, England) (2023). PMID: 36205595 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  176. [176]

    Tomelleri A, Bond M, Marvisi C et al.. “Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure.” Rheumatology (Oxford, England) (2025). PMID: 40366735 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment
  177. [177]

    Tomelleri A, van der Geest KSM, Khurshid MA et al.. “Disease stratification in GCA and PMR: state of the art and future perspectives.” Nature reviews. Rheumatology (2023). PMID: 37308659 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  178. [178]

    Camellino D, Matteson EL, Buttgereit F et al.. “Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.” Nature reviews. Rheumatology (2020). PMID: 32759996 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
  179. [179]

    Han X, He Y, Yang J et al.. “Superior correlation with clinical activity and unique detection patterns: a prospective study of FAPI versus FDG-PET in polymyalgia rheumatica and giant cell arteritis.” European journal of nuclear medicine and molecular imaging (2026). PMID: 42020812 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  180. [180]

    Michailidou D, Dejaco C, Ahlman M et al.. “Vascular imaging as an endpoint in clinical trials of giant cell arteritis.” Clinical and experimental rheumatology (2026). PMID: 42018344 ↗

    L5TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  181. [181]

    Brenac G, Bernard A, Lemogne B et al.. “Orbital MRI for diagnosing giant cell arteritis in cases of anterior ischaemic optic neuropathy.” RMD open (2026). PMID: 41730612 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  182. [182]

    Duftner C, Redlinger N, Bruyn GA et al.. “Reliability of the OMERACT Giant cell arteritis Ultrasonography Score (OGUS): results of a patient-based exercise involving experts and non-experts in vascular ultrasonography.” RMD open (2025). PMID: 39753294 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  183. [183]

    Schremmer T, Dejaco C, Recker F et al.. “OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritis.” RMD open (2025). PMID: 39915246 ↗

    L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  184. [184]

    Matza MA, Dagincourt N, Mohan SV et al.. “Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.” RMD open (2023). PMID: 37024237 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
  185. [185]

    Petzinna SM, von der Emde L, Esser J et al.. “Optical coherence tomography angiography detects retinal microvascular changes in giant cell arteritis: the potential protective role of aortitis.” RMD open (2025). PMID: 41213713 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  186. [186]

    Tomelleri A, Dejaco C. “New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis.” RMD open (2024). PMID: 38395453 ↗

    L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  187. [187]

    Seitz L, Bucher S, Bütikofer L et al.. “DWI scrolling artery sign for the diagnosis of giant cell arteritis: a pattern recognition approach.” RMD open (2024). PMID: 38519109 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  188. [188]

    Schmalzing M, Froehlich M, Strunz PP et al.. “Calprotectin and serum amyloid A for disease activity assessment in giant cell arteritis and polymyalgia rheumatica: results from a prospective single-centre cohort study.” Rheumatology international (2026). PMID: 41779206 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  189. [189]

    Ichimata S, Yoshinaga T, Sato M et al.. “Giant Cell Arteritis With Medin-Derived Amyloid (AMed) Deposition in a Patient With COVID-19: An Autopsy Case.” Pathology international (2026). PMID: 41795795 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  190. [190]

    Glynn T, Leech MT, Goergen SK et al.. “A Diagnostic Headache.” The Medical journal of Australia (2026). PMID: 41772926 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Special Populations, Pregnancy & Fertility
  191. [191]

    Beydon M, Lacaille D, Fautrel B et al.. “Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database.” RMD open (2026). PMID: 42414038 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  192. [192]

    Hellmich B, Agueda A, Monti S et al.. “2018 Update of the EULAR recommendations for the management of large vessel vasculitis.” Annals of the rheumatic diseases (2019). PMID: 31270110 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
  193. [193]

    Quinn KA, Tan S, Verdijk P et al.. “18F-Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment Within a Randomized Controlled Trial in Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41940456 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  194. [194]

    Langford CA, Cuthbertson D, Ytterberg SR et al.. “A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28133925 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  195. [195]

    Dejaco C, Kerschbaumer A, Aletaha D et al.. “Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.” Annals of the rheumatic diseases (2024). PMID: 36828585 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History, Prevention, Screening & Surveillance
  196. [196]

    Stone JH, Tuckwell K, Dimonaco S et al.. “Trial of Tocilizumab in Giant-Cell Arteritis.” The New England journal of medicine (2017). PMID: 28745999 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  197. [197]

    Alessi HD, Quinn KA, Ahlman MA et al.. “Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A Single-Center Prospective Study.” Arthritis care & research (2023). PMID: 35762866 ↗

    L2COHORTCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  198. [198]

    Christ L, Seitz L, Scholz G et al.. “Efficacy of tocilizumab monotherapy after ultrashort glucocorticoid administration to treat giant cell arteritis: three-year follow-up.” Rheumatology (Oxford, England) (2025). PMID: 40478774 ↗

    L4TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  199. [199]

    Hysa E, Bond M, Ehlers L et al.. “Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.” Rheumatology (Oxford, England) (2024). PMID: 37672017 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
  200. [200]

    Duftner C, Dejaco C, Sepriano A et al.. “Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations.” RMD open (2018). PMID: 29531788 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  201. [201]

    van der Geest KS, Abdulahad WH, Chalan P et al.. “Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24623536 ↗

    L3OTHERCited in: Severity, Disease Activity & Risk Stratification
  202. [202]

    Grayson PC, Alehashemi S, Bagheri AA et al.. “18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29145713 ↗

    L2OTHERCited in: Severity, Disease Activity & Risk Stratification
  203. [203]

    Secada-Gómez C, Loricera J, Martín-Gutiérrez A et al.. “Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.” Arthritis care & research (2026). PMID: 41531143 ↗

    L3OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  204. [204]

    Xu S, Jiemy WF, Boots AMH et al.. “Altered Plasma Levels and Tissue Expression of Fibroblast Activation Protein Alpha in Giant Cell Arteritis.” Arthritis care & research (2024). PMID: 38685696 ↗

    L3OTHERCited in: Severity, Disease Activity & Risk Stratification
  205. [205]

    García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G et al.. “Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.” Arthritis care & research (2010). PMID: 20535794 ↗

    L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related
  206. [206]

    Misra DP, Mukhtyar CB, Chandwar K et al.. “The fragility of randomized controlled trials in large vessel vasculitis.” Autoimmunity reviews (2025). PMID: 40865894 ↗

    L1SR_MA_RCTCited in: Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  207. [207]

    Stone JH, Han J, Aringer M et al.. “Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.” The Lancet. Rheumatology (2021). PMID: 38279390 ↗

    L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  208. [208]

    Unizony S, Matza MA, Jarvie A et al.. “Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.” The Lancet. Rheumatology (2023). PMID: 38251564 ↗

    L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  209. [209]

    Christ L, Seitz L, Scholz G et al.. “Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.” The Lancet. Rheumatology (2021). PMID: 38287611 ↗

    L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  210. [210]

    Stone JH, Buttgereit F, Saraux A et al.. “Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.” The New England journal of medicine (2026). PMID: 42234540 ↗

    L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  211. [211]

    Borresen SW, Hansen SB, Al-Jorani H et al.. “Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study).” BMJ open (2026). PMID: 42276802 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  212. [212]

    Dreyer AF, Hansen SB, Borresen SW et al.. “Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol.” BMJ open (2026). PMID: 41638742 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  213. [213]

    Samson M, Fournel I, Bourredjem A et al.. “Immediate versus gradual TocilizuMab discontinuAtion in GIant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial.” BMJ open (2025). PMID: 41067765 ↗

    L5TRIAL_NONRANDOMCited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  214. [214]

    Antonio AA, Santos RN, Abariga SA. “Tocilizumab for giant cell arteritis.” The Cochrane database of systematic reviews (2022). PMID: 35560150 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  215. [215]

    Antonio AA, Santos RN, Abariga SA. “Tocilizumab for giant cell arteritis.” The Cochrane database of systematic reviews (2021). PMID: 34420204 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  216. [216]

    Clifford AH, Thai J, Yip A et al.. “Follow-Up 18F-Fluorodeoxyglucose Positron Emission Tomography in Treated Patients With Giant Cell Arteritis: A Systematic Review and Metaanalysis.” The Journal of rheumatology (2026). PMID: 42140639 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  217. [217]

    Dejaco C, Singh YP, Perel P et al.. “2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.” Annals of the rheumatic diseases (2015). PMID: 26359488 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  218. [218]

    Keller KK, Mukhtyar CB, Nielsen AW et al.. “Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group.” Annals of the rheumatic diseases (2024). PMID: 38050004 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  219. [219]

    Maz M, Chung SA, Abril A et al.. “2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34235884 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  220. [220]

    Cid MC, Unizony SH, Blockmans D et al.. “Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.” Annals of the rheumatic diseases (2022). PMID: 35264321 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  221. [221]

    Felten L, Leuchten N, Aringer M. “Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study.” Rheumatology (Oxford, England) (2022). PMID: 34487149 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  222. [222]

    Therkildsen P, Nielsen BD, de Thurah A et al.. “All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study.” Rheumatology (Oxford, England) (2022). PMID: 34164660 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  223. [223]

    Mensch N, Hemmig AK, Aschwanden M et al.. “Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.” RMD open (2023). PMID: 37460275 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  224. [224]

    Ricordi C, Marvisi C, Macchioni P et al.. “Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies.” RMD open (2024). PMID: 39740930 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  225. [225]

    Carnota-Méndez P, Remolí-Sargues L, Copete S et al.. “Clinical Guidelines for the Diagnosis and Management of Retinal Artery Occlusions by the Spanish Society of Retina and Vitreous.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41818386 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  226. [226]

    Schenning LCM, van Onna M, Tas SW. “Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits.” The Lancet. Rheumatology (2025). PMID: 41418799 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  227. [227]

    Mackie SL, Brouwer E, Conway R et al.. “Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective.” The Lancet. Rheumatology (2020). PMID: 33521671 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  228. [228]

    Guemara R, Pieren A, Brulhart L. “Angioinvasive aspergillosis mimicking giant cell arteritis in an 81-year-old man with jaw pain and vision loss.” RMD open (2022). PMID: 36418085 ↗

    L4CASE_REPORTCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  229. [229]

    Buttgereit F, Matteson EL, Dejaco C et al.. “Prevention of glucocorticoid morbidity in giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29982779 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  230. [230]

    Baral B, Parajuli M, Pinilla J et al.. “Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” ARP rheumatology (2025). PMID: 40629823 ↗

    L1SR_MA_RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  231. [231]

    Schweiger L, Meinitzer A, Szolar D et al.. “Correlation and Risk Assessment of Inflammation-Based Parameters on Cardiovascular Parameters and Clinical Events in Giant Cell Arteritis: A Retrospective Study.” International journal of molecular sciences (2025). PMID: 40725261 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  232. [232]

    Evans J, Steel L, Borg F et al.. “Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.” RMD open (2016). PMID: 26819753 ↗

    L5OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  233. [233]

    Esen I, Arends S, Dalsgaard Nielsen B et al.. “Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort.” RMD open (2023). PMID: 36631159 ↗

    L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  234. [234]

    Malich L, Gühne F, Hoffmann T et al.. “Distribution patterns of arterial affection and the influence of glucocorticoids on 18F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis.” RMD open (2022). PMID: 35953239 ↗

    L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  235. [235]

    Prieto-González S, Terrades-García N, Corbera-Bellalta M et al.. “Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.” RMD open (2017). PMID: 29299342 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  236. [236]

    Buttgereit F, Boyadzhieva Z, Reisch M et al.. “[S2e guidelines on the treatment of polymyalgia rheumatica: update 2024 : Evidence-based guidelines of the German Society for Rheumatology and Clinical Immunology (DGRh), the Austrian Society for Rheumatology and Rehabilitation (ÖGR) and the Swiss Society for Rheumatology (SGR) and the participating medical scientific specialist societies and other organizations].” Zeitschrift fur Rheumatologie (2025). PMID: 40560440 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  237. [237]

    Seror R, Baron G, Hachulla E et al.. “Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.” Annals of the rheumatic diseases (2013). PMID: 23897775 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  238. [238]

    Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L et al.. “A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.” Annals of the rheumatic diseases (2007). PMID: 18086726 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  239. [239]

    Adler S, Reichenbach S, Gloor A et al.. “Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.” Rheumatology (Oxford, England) (2019). PMID: 30915462 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  240. [240]

    Gloor AD, Yerly D, Adler S et al.. “Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29961816 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  241. [241]

    Reichenbach S, Adler S, Bonel H et al.. “Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.” Rheumatology (Oxford, England) (2018). PMID: 29529280 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  242. [242]

    Visvanathan S, Rahman MU, Hoffman GS et al.. “Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.” Rheumatology (Oxford, England) (2011). PMID: 21873264 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  243. [243]

    Monti S, Águeda AF, Luqmani RA et al.. “Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.” RMD open (2019). PMID: 31673411 ↗

    L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  244. [244]

    Chaddock NJM, Harden CJ, Sorensen L et al.. “Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis.” Annals of the rheumatic diseases (2025). PMID: 39919905 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  245. [245]

    Lozano E, Segarra M, García-Martínez A et al.. “Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis.” Annals of the rheumatic diseases (2007). PMID: 17584806 ↗

    L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  246. [246]

    van Sleen Y, van der Geest KSM, Buisman AM et al.. “Humoral SARS-CoV-2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster.” Arthritis care & research (2023). PMID: 37332051 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
  247. [247]

    Scolnik M, Brance ML, Fernández-Ávila DG et al.. “Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis.” The Lancet. Rheumatology (2022). PMID: 38261393 ↗

    L1REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  248. [248]

    de Boysson H, Ly KH, Geffray L et al.. “Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial.” Arthritis research & therapy (2025). PMID: 40483523 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  249. [249]

    Hansen SB, Dreyer AF, Jørgensen NT et al.. “Changes in Adrenal Function and Insufficiency Symptoms After Cessation of Prednisolone.” JAMA network open (2025). PMID: 40100216 ↗

    L4RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  250. [250]

    Deshayes S, Ly KH, Rieu V et al.. “Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments.” Rheumatology (Oxford, England) (2021). PMID: 33742671 ↗

    L4CASE_REPORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  251. [251]

    Xu C, Denney WS, Liu Y et al.. “Population Pharmacokinetics and Exposure-Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica.” Journal of clinical pharmacology (2025). PMID: 40105153 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  252. [252]

    Shirai T, Yoshida T, Sugano E et al.. “Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41692437 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  253. [253]

    Rousset S, Treiner E, Moulis G et al.. “High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis.” Rheumatology (Oxford, England) (2020). PMID: 31518431 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  254. [254]

    Quick V, Abusalameh M, Ahmed S et al.. “Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.” Rheumatology (Oxford, England) (2024). PMID: 37952183 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  255. [255]

    van der Geest KS, Abdulahad WH, Rutgers A et al.. “Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.” Rheumatology (Oxford, England) (2015). PMID: 25724206 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  256. [256]

    Mahr A, Belhassen M, Paccalin M et al.. “Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data.” Rheumatology (Oxford, England) (2020). PMID: 31382293 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  257. [257]

    Schönau V, Roth J, Tascilar K et al.. “Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.” Rheumatology (Oxford, England) (2021). PMID: 33831144 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  258. [258]

    Terribili R, Grazzini S, Conticini E et al.. “Safety and Efficacy of Long-Term Tocilizumab in a Cohort of Patients with Giant Cell Arteritis: An Italian Monocentric Retrospective Study.” Biologics : targets & therapy (2024). PMID: 39376549 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring
  259. [259]

    van Sleen Y, van der Geest KSM, Reitsema RD et al.. “Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica.” RMD open (2022). PMID: 39552442 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  260. [260]

    Abhishek A, Iagnocco A, Bijlsma JWJ et al.. “Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.” RMD open (2018). PMID: 30271621 ↗

    L4OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  261. [261]

    de Boysson H, Devauchelle-Pensec V, Agard C et al.. “Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).” La Revue de medecine interne (2024). PMID: 39500637 ↗

    L5GUIDELINECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  262. [262]

    Régent A, Redeker S, Deroux A et al.. “Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.” The Journal of rheumatology (2016). PMID: 27182063 ↗

    L4COHORTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  263. [263]

    Venhoff N, Schmidt WA, Lamprecht P et al.. “Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.” Trials (2021). PMID: 34404463 ↗

    L5TRIAL_NONRANDOMCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  264. [264]

    Samson M, Espígol-Frigolé G, Terrades-García N et al.. “Biological treatments in giant cell arteritis & Takayasu arteritis.” European journal of internal medicine (2017). PMID: 29146018 ↗

    L5REVIEW_NARRATIVECited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  265. [265]

    Martín-Gutiérrez A, Loricera J, Prieto-Peña D et al.. “Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of 196 patients.” Seminars in arthritis and rheumatism (2025). PMID: 41218409 ↗

    L2OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  266. [266]

    Calderón-Goercke M, Loricera J, Aldasoro V et al.. “Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.” Seminars in arthritis and rheumatism (2019). PMID: 30655091 ↗

    L4OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  267. [267]

    Márquez A, Hernández-Rodríguez J, Cid MC et al.. “Influence of the IL17A locus in giant cell arteritis susceptibility.” Annals of the rheumatic diseases (2014). PMID: 24919468 ↗

    L3SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  268. [268]

    Russell MD, Schaffer A, Yang Z et al.. “Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.” The Lancet. Rheumatology (2026). PMID: 42379213 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  269. [269]

    Chrysidis S, Døhn UM, Terslev L et al.. “Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, non-interventional, cohort study.” The Lancet. Rheumatology (2021). PMID: 38287632 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  270. [270]

    Cunningham KY, Hur B, Gupta VK et al.. “Plasma proteome profiling in giant cell arteritis.” Annals of the rheumatic diseases (2024). PMID: 39153834 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  271. [271]

    Ansalone C, McAllister S, Pickerill ES et al.. “Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response.” Annals of the rheumatic diseases (2025). PMID: 41109780 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  272. [272]

    Borrego-Yaniz G, Márquez A, Estupiñán-Moreno E et al.. “Genome-Wide DNA Methylation Study Reveals Specific Signatures in the Affected Arterial Tissue of Patients With Giant Cell Arteritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 40826980 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  273. [273]

    Maillet F, Nguyen Y, Espitia O et al.. “Association between large vessel vasculitis and inflammatory bowel disease: a case-control study.” Rheumatology (Oxford, England) (2025). PMID: 39898825 ↗

    L3CASE_CONTROLCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  274. [274]

    Henderson BA, Mehta VR, Holck P et al.. “Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska.” Arthritis care & research (2025). PMID: 39936239 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  275. [275]

    Germanò G, Macchioni P, Possemato N et al.. “Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings.” Arthritis care & research (2016). PMID: 27059104 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  276. [276]

    Chu R, Foster C, Ali M et al.. “Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records.” The Lancet. Rheumatology (2020). PMID: 38273631 ↗

    L4REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  277. [277]

    Carmona FD, González-Gay MA, Martín J. “Genetic component of giant cell arteritis.” Rheumatology (Oxford, England) (2013). PMID: 23843109 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility
  278. [278]

    Kaymakci MS, Berry GJ, Langenfeld HE et al.. “Subclinical aortic inflammation in patients with polymyalgia rheumatica.” Rheumatology (Oxford, England) (2024). PMID: 39024049 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  279. [279]

    Watanabe N, Hara Y, Nishito Y et al.. “Tissue degrading and remodelling molecules in giant cell arteritis.” Rheumatology (Oxford, England) (2025). PMID: 39837478 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  280. [280]

    Xu S, Jiemy WF, van Sleen Y et al.. “Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis.” Rheumatology (Oxford, England) (2025). PMID: 40084998 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  281. [281]

    Nielsen BD, Kristensen S, Donskov A et al.. “Correction: The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica.” Frontiers in medicine (2026). PMID: 41987771 ↗

    L3COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  282. [282]

    Bai Y, Wang Z, Zhang C. “Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis.” Open medicine (Warsaw, Poland) (2026). PMID: 41798905 ↗

    L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  283. [283]

    Robbins D, Khurshid MA, Neil L et al.. “A Delphi survey of patients and clinicians on a unified and stratified approach to managing GCA-PMR spectrum disease.” Rheumatology (Oxford, England) (2026). PMID: 42397190 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  284. [284]

    Colina M. “Beyond clinical criteria: emerging biomarkers and advanced imaging in the diagnosis, monitoring and treatment of vasculitides.” Frontiers in medicine (2026). PMID: 42396140 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  285. [285]

    Seidlberger S, Castañeda S, Wietzorrek G et al.. “Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.” Arthritis research & therapy (2026). PMID: 42387612 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility
  286. [286]

    Molina-Collada J, Cowley S, Kirby C et al.. “Prognostic value of quantifying vascular inflammation through ultrasound in patients with giant cell arteritis: the MAGiCUS study.” Rheumatology (Oxford, England) (2026). PMID: 42378435 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  287. [287]

    Pacoureau L, Barde F, Seror R et al.. “Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis.” RMD open (2023). PMID: 37949615 ↗

    L3SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  288. [288]

    Robson JC, Kiran A, Maskell J et al.. “The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.” Annals of the rheumatic diseases (2013). PMID: 24095936 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  289. [289]

    Schmidt WA, Moll A, Seifert A et al.. “Prognosis of large-vessel giant cell arteritis.” Rheumatology (Oxford, England) (2008). PMID: 18625659 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
  290. [290]

    Esen I, Jiemy WF, van Sleen Y et al.. “Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis.” Rheumatology (Oxford, England) (2022). PMID: 34730794 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
  291. [291]

    Macchioni P, Boiardi L, Muratore F et al.. “Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study.” Rheumatology (Oxford, England) (2019). PMID: 30517710 ↗

    L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
  292. [292]

    Hill CL, Cole A, Rischmueller M et al.. “Risk of cancer in patients with biopsy-proven giant cell arteritis.” Rheumatology (Oxford, England) (2010). PMID: 20089693 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
  293. [293]

    Martire MV, Cipolletta E, Di Matteo A et al.. “Is the intima-media thickness of temporal and axillary arteries influenced by cardiovascular risk?” Rheumatology (Oxford, England) (2021). PMID: 33547776 ↗

    L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
  294. [294]

    Benichou A, De Gaulmyn M, Guimbretiere G et al.. “Aortitis accelerates the growth rate of thoracic aortic aneurysms.” RMD open (2026). PMID: 42276733 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  295. [295]

    van der Veen MJ, Dinant HJ, van Booma-Frankfort C et al.. “Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?” Annals of the rheumatic diseases (1996). PMID: 8733437 ↗

    L1RCTCited in: History and Evolution of Treatment
  296. [296]

    Atchia I, Brown AK, Chitale S et al.. “Recommendations for rheumatology ultrasound training and practice in the UK.” Rheumatology (Oxford, England) (2021). PMID: 33167033 ↗

    L5GUIDELINECited in: History and Evolution of Treatment
  297. [297]

    Li L, Neogi T, Jick S. “Mortality in Patients With Giant Cell Arteritis: A Cohort Study in UK Primary Care.” Arthritis care & research (2018). PMID: 29409137 ↗

    L3COHORTCited in: History and Evolution of Treatment, Prognosis & Natural History
  298. [298]

    Askling J, Klareskog L, Hjalgrim H et al.. “Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.” Annals of the rheumatic diseases (2005). PMID: 15843445 ↗

    L3CASE_CONTROLCited in: History and Evolution of Treatment
  299. [299]

    Blockmans D. “Why, how and when to look for occult giant cell arteritis in patients with polymyalgia rheumatica.” Rheumatology (Oxford, England) (2025). PMID: 40071419 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  300. [300]

    Schmidt WA. “Biopsy vs imaging in the diagnosis of giant cell arteritis. Viewpoint 1: in favour of imaging.” Rheumatology (Oxford, England) (2025). PMID: 40071427 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  301. [301]

    Hall S, Persellin S, Lie JT et al.. “The therapeutic impact of temporal artery biopsy.” Lancet (London, England) (1983). PMID: 6139569 ↗

    L3OTHERCited in: History and Evolution of Treatment
  302. [302]

    Dumont A, Espitia O, Samson M et al.. “Complete PET/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab.” RMD open (2026). PMID: 41895800 ↗

    L4OTHERCited in: History and Evolution of Treatment, Prognosis & Natural History
  303. [303]

    Sebastian A, Kayani A, Prieto-Pena D et al.. “Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool.” RMD open (2020). PMID: 33161376 ↗

    L4OTHERCited in: History and Evolution of Treatment
  304. [304]

    Águeda AF, Monti S, Luqmani RA et al.. “Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.” RMD open (2019). PMID: 31673416 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  305. [305]

    Andel PM, Chrysidis S, Geiger J et al.. “Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist.” Rheumatology (Oxford, England) (2021). PMID: 34255830 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  306. [306]

    Czihal M, Köhler A, Lottspeich C et al.. “Temporal artery compression sonography for the diagnosis of giant cell arteritis in elderly patients with acute ocular arterial occlusions.” Rheumatology (Oxford, England) (2021). PMID: 33123722 ↗

    L3OTHERCited in: Special Populations, Pregnancy & Fertility
  307. [307]

    Andel PM, Diamantopoulos AP, Myklebust G et al.. “Vasculitis distribution and clinical characteristics in giant cell arteritis: a retrospective study using the new 2022 ACR/EULAR classification criteria.” Frontiers in medicine (2023). PMID: 38020143 ↗

    L4COHORTCited in: Special Populations, Pregnancy & Fertility
  308. [308]

    Lester S, Hewitt AW, Ruediger CD et al.. “PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis.” RMD open (2016). PMID: 27110387 ↗

    L5OTHERCited in: Special Populations, Pregnancy & Fertility
  309. [309]

    Czihal M, Köhler A, Prearo I et al.. “Hyperechogenic intimal lesions and wall thickness of the temporal and facial arteries in elderly patients with arterial occlusions of the eye.” RMD open (2021). PMID: 34544823 ↗

    L4OTHERCited in: Special Populations, Pregnancy & Fertility
  310. [310]

    Lee JI, Park JW, Jung Y et al.. “Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study.” Journal of rheumatic diseases (2024). PMID: 38957359 ↗

    L4COHORTCited in: Special Populations, Pregnancy & Fertility
  311. [311]

    Gil W, Kodjikian L, Andre M et al.. “Uveitis in Giant Cell Arteritis: A Retrospective Study of Seven Observational Cases and Literature Review.” Ocular immunology and inflammation (2023). PMID: 37815855 ↗

    L4COHORTCited in: Special Populations, Pregnancy & Fertility
  312. [312]

    Dvir M, Almhanni G, Qaisar H et al.. “When Occipital Artery Biopsy is Preferred to Temporal Biopsy for Giant Cell Arteritis: A Step-By-Step Description of the Surgical Technique.” Mayo Clinic proceedings. Innovations, quality & outcomes (2024). PMID: 38283098 ↗

    L5CASE_REPORTCited in: Special Populations, Pregnancy & Fertility
  313. [313]

    Jakobsson K, Jacobsson L, Warrington K et al.. “Body mass index and the risk of giant cell arteritis: results from a prospective study.” Rheumatology (Oxford, England) (2014). PMID: 25193806 ↗

    L3COHORTCited in: Prevention, Screening & Surveillance
  314. [314]

    Wadström K, Jacobsson LTH, Mohammad AJ et al.. “Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study.” Rheumatology (Oxford, England) (2023). PMID: 36255228 ↗

    L3COHORTCited in: Prevention, Screening & Surveillance
  315. [315]

    Baerlecken NT, Linnemann A, Gross WL et al.. “Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica.” Annals of the rheumatic diseases (2012). PMID: 22228484 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  316. [316]

    Papo M, Friedrich C, Delaval L et al.. “Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.” Rheumatology (Oxford, England) (2022). PMID: 33836046 ↗

    L3CASE_CONTROLCited in: Prevention, Screening & Surveillance
  317. [317]

    Sverdlichenko I, Xie JS, Lu B et al.. “Atypical Signs and Symptoms of Giant Cell Arteritis: A Systematic Review.” Journal of general internal medicine (2024). PMID: 39482474 ↗

    L4SR_OBSCited in: Prevention, Screening & Surveillance
  318. [318]

    Makhzoum JP, Baati Y, Tanase O et al.. “Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis.” Systematic reviews (2024). PMID: 38978122 ↗

    L5SR_OBSCited in: Prevention, Screening & Surveillance
  319. [319]

    Antonini L, Dumont A, Lavergne A et al.. “Real-life analysis of the causes of death in patients consecutively followed for giant cell arteritis in a French centre of expertise.” Rheumatology (Oxford, England) (2021). PMID: 33693495 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…